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BACKGROUND
In the majority of patients with chronic spontaneous urticaria, most currently avail-
able therapies do not result in complete symptom control. Ligelizumab is a next-
generation high-affinity humanized monoclonal anti-IgE antibody. Data are limited 
regarding the dose–response relationship of ligelizumab and the efficacy and safety 
of ligelizumab as compared with omalizumab and placebo in patients who have 
moderate-to-severe chronic spontaneous urticaria that is inadequately controlled 
with H1-antihistamines at approved or increased doses, alone or in combination with 
H2-antihistamines or leukotriene-receptor antagonists.
METHODS
In a phase 2b dose-finding trial, we randomly assigned patients to receive ligeliz-
umab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or 
placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a 
single 120-mg dose of ligelizumab. Disease symptoms of hives, itch, and angioedema 
were monitored by means of weekly activity scores. The main objective was to deter-
mine a dose–response relationship for the complete control of hives (indicated by a 
weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating 
greater severity); the primary end point of this response was assessed at week 12. 
Complete symptom control was indicated by a weekly urticaria activity score of 0 (on 
a scale from 0 to 42, with higher scores indicating greater severity). Safety was ana-
lyzed throughout the trial.
RESULTS
A total of 382 patients underwent randomization. At week 12, a total of 30%, 51%, 
and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of 
ligelizumab had complete control of hives, as compared with 26% of the patients in 
the omalizumab group and no patients in the placebo group. A dose–response rela-
tionship was established. At week 12, a total of 30%, 44%, and 40% of the patients 
treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete 
control of symptoms, as compared with 26% of the patients in the omalizumab group 
and no patients in the placebo group. In this small and short trial, no safety concerns 
regarding ligelizumab or omalizumab emerged.
CONCLUSIONS
A higher percentage of patients had complete control of symptoms of chronic sponta-
neous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab 
or placebo. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT02477332.)
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Chronic spontaneous urticaria is a skin disorder that is characterized by the occurrence of itchy wheals (hives), angio-
edema, or both for 6 weeks or more in the ab-
sence of specific external stimuli.1,2 Studies have 
indicated that chronic spontaneous urticaria has 
a prevalence of approximately 1 case per 200 per-
sons in adult European populations.3-5 Evidence 
suggests that chronic spontaneous urticaria has 
a long duration6,7 and can have a negative effect 
on quality of life.6,8 The pathogenesis of chronic 
spontaneous urticaria is not fully clear, but it is 
known to involve autoimmune mechanisms in 
most patients by means of IgG autoantibodies 
against the high-affinity receptor for the Fc region 
of IgE (FcεRI) or less frequently against IgE and 
IgE autoantigens.9-13
Standard first-line treatment of chronic spon-
taneous urticaria consists of nonsedating (second-
generation) H1-antihistamines at locally approved 
doses, with escalation up to four times the ap-
proved dose used off-label as second-line treat-
ment; even so, the disease is still uncontrolled in 
some patients.1,14,15 The revised guidelines regard-
ing the treatment of urticaria from the European 
Academy of Allergology and Clinical Immunol-
ogy (EAACI), the Global Allergy and Asthma 
European Network (GA2LEN), the European 
Dermatology Forum (EDF) and the World Al-
lergy Organization (WAO)1 recommend the use 
of omalizumab as add-on third-line therapy to 
H1-antihistamines. The goal of therapy, as noted 
in the current treatment guidelines, is com-
plete control of the disease, yet some patients 
have symptoms that remain uncontrolled with 
the current standard of care.1 To date, add-on 
therapy with omalizumab has been the most 
effective treatment in patients who continue to 
have symptoms while they are taking H1-anti-
histamines,16-18 but some patients do not have 
a response, and better treatment options are 
needed.19-22
Ligelizumab is a new high-affinity humanized 
monoclonal anti-IgE antibody that has previously 
shown dose-dependent and time-dependent sup-
pression of free IgE, basophil FcεRI, basophil 
surface IgE, and skin-prick test responses to al-
lergen that was superior in extent and duration 
to that observed with omalizumab.23 In a phase 
2b trial, we examined the efficacy and safety of 
ligelizumab as compared with omalizumab and 
placebo in patients with chronic spontaneous 
urticaria that was inadequately controlled with 
standard-of-care therapy including H1-antihista-
mines.
Me thods
Trial Design and Oversight
This phase 2b, dose-finding, multicenter, random-
ized, double-blind, active-controlled and placebo-
controlled trial was designed to establish a 
dose–response relationship for ligelizumab and 
to evaluate its efficacy and safety as compared 
with omalizumab and placebo (Fig. 1). The trial 
consisted of a screening period (days −14 to 1), 
a treatment period (days 1 to 140 [20 weeks]), 
and a follow-up period after the cessation of the 
trial regimens (days 141 to 309 [24 weeks]). Pa-
tients who remained in the follow-up period for 
at least 12 weeks and had active disease (defined 
as a mean weekly urticaria activity score [mea-
sured twice daily] of ≥12; scores range from 0 to 
42, with higher scores indicating greater sever-
ity; minimally important difference [MID], 9.5 to 
10.0 points)24-27 were eligible to enter an extension 
study (ClinicalTrials.gov number, NCT02649218) 
from week 32 onward. The trial protocol, with 
the statistical analysis plan, is available with the 
full text of this article at NEJM.org.
This trial was designed and sponsored by 
Novartis Pharma. The institutional review board 
at each participating center approved the proto-
col. Patients provided written informed consent 
before any assessment was performed. Data were 
collected by the trial investigators according to 
Good Clinical Practice guidelines and were ana-
lyzed by the sponsor. The first draft of the 
manuscript was written by a medical writer paid 
by the sponsor, with critical input and approval 
from all authors. All the authors critically re-
viewed each manuscript draft, provided substan-
tial input on the content, and made the decision 
to submit the manuscript for publication. The 
authors vouch for the accuracy and completeness 
of the data and for the fidelity of the trial to the 
protocol.
Patients
Eligible patients were 18 to 75 years of age and 
had chronic spontaneous urticaria that was in-
adequately controlled with H1-antihistamines at 
A Quick Take is 
available at 
NEJM.org 
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approved or increased doses alone or in combi-
nation with H2-antihistamines or leukotriene-
receptor antagonists. Key inclusion criteria were 
the following: mild-to-moderate chronic sponta-
neous urticaria, defined as a weekly urticaria 
activity score of at least 16 (disease activity cat-
egories are as follows: 0, symptom free; 1 to 6, 
well-controlled urticaria; 7 to 15, mild urticaria; 
16 to 27, moderate urticaria; and 28 to 42, severe 
urticaria26); a weekly hives-severity score of at 
least 8 (scores range from 0 to 21, with higher 
values indicating greater severity; MID, 5.0 to 5.5 
points)27 during the 7 days before randomization 
(day 1); and an in-clinic urticaria activity score of 
at least 4 (scores range from 1 to 6, with higher 
values indicating greater severity; MID, not avail-
able) on at least one of the screening visit days. 
Key exclusion criteria were the following: previ-
ous exposure to omalizumab or ligelizumab, 
any other skin disease that is associated with 
chronic itching that might confound the trial 
evaluations and results, and a clearly defined 
underlying cause of chronic urticaria other than 
chronic spontaneous urticaria (e.g., inducible 
urticaria).
The demographic and clinical characteristics 
of the patients and the disease activity were elic-
ited or measured at baseline. The Chronic Urti-
caria Index (CU Index; Viracor-IBT Laboratories), 
an in vitro basophil histamine-release assay in 
which a serum sample obtained from a patient 
is mixed with donor basophils and the released 
histamine levels are measured by a quantitative 
enzyme immunoassay, was performed at base-
line. A positive CU Index (scores range from 1 to 
50, with scores ≥10 representing a positive re-
sult) indicates that a patient has either an auto-
immune basis for the urticaria or an alternative 
histamine-releasing factor that has been associ-
ated with greater disease severity than that in 
patients with a negative CU Index.28,29 The serum 
samples for this analysis were obtained centrally 
and analyzed by Viracor-IBT Laboratories. From 
the time that samples were obtained until analy-
sis, they were kept frozen to ensure sample 
integrity.
Figure 1. Trial Design.
The single 120‑mg dose of ligelizumab was chosen in order to characterize the pharmacokinetics and pharmacody‑
namics of ligelizumab. Data from this group were used to assess the duration of response and to correlate this in‑
formation with the concentration of drug in the serum at the time when symptoms reappeared. Patients who remained 
in the follow‑up period for at least 12 weeks and had active disease (weekly urticaria activity score of ≥12 on a scale 
from 0 to 42, with higher scores indicating greater severity) could enter an extension study from week 32 onward. 
SD denotes single dose.
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Trial Procedures
Patients were randomly assigned, in a 2:2:2:1:1:1 
ratio, to receive one of the following trial regi-
mens: 240 mg of ligelizumab every 4 weeks, 72 mg 
of ligelizumab every 4 weeks, 300 mg of omaliz-
umab every 4 weeks, 24 mg of ligelizumab every 
4 weeks, placebo every 4 weeks, or a single 120-mg 
dose of ligelizumab at week 0 followed by placebo 
every 4 weeks; the treatment period was 20 weeks 
(Fig. 1). The single 120-mg dose of ligelizumab 
was used to gain blinded washout information, 
to determine the level of ligelizumab in serum 
that was associated with the return of itch and 
hives symptoms, and to identify an appropriate 
administration interval for phase 3 trials.
Adjustments to the doses of trial agents were 
not permitted. Nonsedating H1-antihistamines 
were used as background medication and as res-
cue medication as needed during the screening, 
treatment, and follow-up periods. This trial re-
quired concurrent use of H1-antihistamines (at 
locally approved doses or at increased doses up 
to four times the locally approved dose) alone 
or in combination with H2-antihistamines or 
leukotriene-receptor antagonists (montelukast, 
zafirlukast, or pranlukast) as background medi-
cation. It was recommended that patients con-
tinue taking a stable background medication 
throughout the trial, and patients were not per-
mitted to switch their rescue medications.
End-Point Measures
The main objective of the trial was to establish 
a dose–response relationship with respect to the 
achievement of complete hives response (weekly 
hives-severity score of 0) at week 12. Complete 
hives response was chosen as the primary end 
point because hives were considered to be a more 
objective symptom than itch and are specific to 
chronic spontaneous urticaria; itch is subjective 
and nonspecific and can be of different origins. 
We chose week 12 as the time point for the as-
sessment of the primary end point because this 
was also the time point for the primary end 
point in phase 3 trials of omalizumab.19,20
Secondary end points included the following: 
the efficacy of specific ligelizumab doses of 24 mg, 
72 mg, and 240 mg as compared with omalizu-
mab at a dose of 300 mg with respect to the 
achievement of complete hives response at weeks 
12 and 20; the efficacy of ligelizumab at doses 
of 24 mg, 72 mg, and 240 mg as compared with 
placebo and with omalizumab at a dose of 300 mg 
in the mean change from baseline in the weekly 
hives-severity score, in the weekly itch-severity 
score (scores range from 0 to 21, with higher 
scores indicating greater severity; MID, 4.5 to 
5.0 points), in the weekly urticaria activity score, 
and in the weekly angioedema activity score 
(scores range from 0 to 105, with higher scores 
indicating greater severity; MID, not available); 
and the safety of ligelizumab as compared with 
placebo and with omalizumab at a dose of 300 mg 
during the 20 weeks of the treatment phase and 
24 weeks of follow-up.
Statistical Analysis
The null hypothesis of a constant dose–response 
curve for the primary efficacy end point was 
tested at a significance level of 5% against the 
one-sided alternative hypothesis of a nonconstant 
dose–response curve with the use of the multiple 
comparison procedure and modeling method, 
which indicates the potential dose–response rela-
tionship.30,31 The dose–response curve was mod-
eled as a weighted average of prespecified model 
candidates with the use of bootstrap sampling. 
The dose–response model was derived from test-
ing a range of ligelizumab doses, starting at 24 mg 
and then 72 mg and 240 mg, with placebo con-
sidered to be the zero dose. For the primary 
variable, patients who had data missing because 
of discontinuation before the week 12 assess-
ment were considered not to have had a response, 
regardless of their last available assessment of 
the weekly hives-severity score.
Since the statistical analysis plan did not in-
clude a provision for correcting for multiplicity 
when tests were conducted for secondary or other 
outcomes, results are reported as point esti-
mates with 95% confidence intervals. This was 
a small and clinically nondirective trial. The widths 
of the confidence intervals have not been ad-
justed for multiplicity, so the intervals should 
not be used to infer any effects for secondary 
outcomes.
R esult s
Participants
A total of 574 patients were screened, of whom 
382 were randomly assigned to a trial group. A 
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total of 338 patients (88%) completed the treat-
ment phase of the trial (Fig. S1 in the Supplemen-
tary Appendix, available at NEJM.org). There were 
no notable imbalances among the trial groups 
regarding the demographic and clinical charac-
teristics of the patients at baseline (Table 1).
Primary End Point
The main objective of the trial was achieved, with 
ligelizumab showing a dose–response relation-
ship with respect to the achievement of complete 
hives response (weekly hives-severity score of 0) 
at week 12 (primary end point) in patients with 
chronic spontaneous urticaria. The dose–response 
curve showed a steep dose–response relationship 
with a plateau starting close to the 72-mg dose 
of ligelizumab (Fig. 2A); no further improvement 
in response was noted with the 240-mg dose.
Secondary End Points
At week 12, a total of 30%, 51%, and 42% of the 
patients treated with 24 mg, 72 mg, and 240 mg, 
respectively, of ligelizumab had a complete hives 
response, as compared with 26% of the patients 
in the omalizumab group (Fig. 2B) and no pa-
tients in the placebo group. The response with 
the 72-mg dose of ligelizumab was maintained 
at week 20, with 51% of the patients having a 
response, as compared with 34% of those in the 
omalizumab group. A total of 45% of the pa-
tients in the group that received the 240-mg 
dose of ligelizumab had a response. The response 
regarding itch severity (weekly itch-severity score 
of 0) showed a pattern similar to that seen with 
the weekly hives-severity score. Details are pro-
vided in Figure S2 in the Supplementary Appendix.
At week 12, a total of 30%, 44%, and 40% of 
patients treated with 24 mg, 72 mg, and 240 mg, 
respectively, of ligelizumab had complete control 
of symptoms (weekly urticaria activity score of 0), 
as compared with 26% of the patients in the 
omalizumab group and none of the patients in 
the placebo group (Fig. S2 in the Supplementary 
Appendix). At week 20, a response was observed 
in 39% of the patients who received the 72-mg 
dose of ligelizumab and in 40% of those who 
received the 240-mg dose, as compared with 
31% of those in the omalizumab group and 5% 
of those in the placebo group. After the end of 
the treatment phase, the median time to loss 
of response in patients who had had a response 
at week 20 was 3 weeks, 4 weeks, and 10.5 weeks 
among patients who received 24 mg, 72 mg, and 
240 mg, respectively, of ligelizumab, as compared 
with 4 weeks among patients in the omalizumab 
group and 1 week among those in the placebo 
group.
The median (with interquartile ranges) and 
mean weekly hives-severity scores are shown in 
Figure 3. Patients in the groups that received the 
72-mg or 240-mg doses of ligelizumab had me-
dian weekly hives-severity scores close to 0 from 
weeks 12 to 20. The mean changes from base-
line to week 32 in the weekly hives-severity 
score, itch-severity score, and urticaria activity 
score are shown in Figure S3 in the Supplemen-
tary Appendix. The single 120-mg dose of ligeliz-
umab resulted in suppression of symptoms that 
was similar to that seen with the 72-mg and 
240-mg doses at week 4 and that lasted until 
week 8. At week 12, the mean changes from 
baseline in the angioedema activity score were 
−21.1, −37.6, and −27.3 among patients treated 
with 24 mg, 72 mg, and 240 mg, respectively, 
of ligelizumab, as compared with −23.1 in the 
omalizumab group and −23.6 in the placebo 
group (Fig. S3 in the Supplementary Appendix).
Safety
A higher proportion of adverse events that were 
considered by the investigators to be related to 
treatment was seen in the groups that received 
the 72-mg and 240-mg doses of ligelizumab 
than in the other groups (Table 2). These results 
were driven by mild or moderate injection-site 
reactions (in 4% of the patients in the 72-mg 
group and 7% of those in the 240-mg group) and 
by mild injection-site erythema (in 2% and 6%, 
respectively). All other adverse events that were 
considered to be possibly related to treatment 
during the trial were reported in three or fewer 
patients per group, with no meaningful differ-
ences among the trial groups. Serious adverse 
events were reported in 7%, 2%, and 2% of the 
patients treated with 24 mg, 72 mg, and 240 mg, 
respectively, of ligelizumab, as compared with 
4% of the patients treated with omalizumab and 
9% of those who received placebo.
The most frequently reported adverse events 
(occurring in ≥10% of the patients overall) were 
viral upper respiratory tract infection (in 20%), 
upper respiratory tract infection (in 13%), and 
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Figure 2. Dose–Response Curve for Hives-Severity Response at Week 12 and Forest Plot of the Odds Ratios  
for Response at Week 12.
Panel A shows the dose–response curve with the median of 1000 bootstrap samples; the shaded area indicates the 
20th to 80th percentile. Dots with error bars represent point estimates and an asymptotic 60% confidence interval 
for each dose in observed data. The active comparator was omalizumab. The weekly hives‑severity score measures 
the severity of hives over a period of 7 days on a scale ranging from 0 to 21, with higher scores indicating greater se‑
verity. One sample with an artificial response was created in the placebo group to achieve model fit. Panel B shows 
a forest plot of the odds ratios (ligelizumab vs. omalizumab) for response (defined as a score of 0 on each assess‑
ment) at week 12. The primary end point of complete hives response (weekly hives‑severity score of 0) was assessed 
at week 12. Secondary end points included the weekly itch‑severity and urticaria activity scores. The weekly itch‑ 
severity score measures the severity of itch over a period of 7 days on a scale ranging from 0 to 21, with higher 
scores indicating greater severity. The weekly urticaria activity score is a composite of the weekly itch‑severity and 
hives‑severity scores; the scale ranges from 0 to 42, with higher scores indicating greater severity. Missing data were 
imputed as no response. The statistical model used logistic regression with adjustment for background medication 
type and score on the Chronic Urticaria Index (CU Index); one patient was not included in the model because the 
patient did not have a CU Index score at baseline.
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headache (in 11%). Viral upper respiratory tract 
infection was reported more frequently in the 
placebo group (30%) than in the four groups that 
received ligelizumab (15 to 24%) or in the omaliz-
umab group (20%). No deaths or anaphylaxis 
events were reported in any of the trial groups.
Discussion
Most currently available therapies for chronic 
spontaneous urticaria do not result in complete 
control of symptoms in the majority of patients. 
The main objective of this trial was achieved, 
with a clear dose–response relationship being 
observed with ligelizumab in the achievement of 
complete hives response (weekly hives-severity 
score of 0) at week 12 (primary end point) in 
patients with chronic spontaneous urticaria. Our 
trial showed that 72 mg of ligelizumab, admin-
istered subcutaneously every 4 weeks, resulted in 
complete hives response in 51% of the patients, 
whereas 26% of the patients treated with omaliz-
Figure 3. Hives-Severity Scores from Baseline to Week 32, According to Trial Group.
The horizontal lines within the boxes represent median values, the boxes represent interquartile ranges, and the 
vertical lines represent the data ranges. Colored lines represent mean values. The scale for the weekly hives‑severity 
score ranges from 0 to 21, with higher scores indicating greater severity.
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umab at a dose of 300 mg, which is the dose that 
has been considered to be effective in other 
studies,19-21 had this response.
The frequency of response according to the 
weekly urticaria activity score in the omalizumab 
group at week 12 was lower than in previous 
studies (34 to 44%).19-21 An explanation for this 
finding may be that a higher percentage of pa-
tients in our trial had a positive CU Index (indi-
cating an autoimmune type IIb component to 
their chronic spontaneous urticaria),28 had angio-
edema (Table 1), and had received treatment 
with elevated doses of H1-antihistamines or com-
bination therapies. Previous studies have shown 
that a positive CU Index was associated with 
increased severity of chronic urticaria and that 
significantly more patients with refractory chron-
ic urticaria had a positive CU Index than those 
who had had a response to H1-antihistamines.
28,29
In the current trial, responses according to 
changes from baseline in the weekly hives-sever-
ity score, itch-severity score, and urticaria activity 
score were observed as early as week 4 after re-
ceipt of the 72-mg, 120-mg, and 240-mg doses 
of ligelizumab, thus indicating an onset of ac-
tion within this time frame for ligelizumab. The 
suppression of symptoms after the single 120-mg 
dose of ligelizumab was maintained until week 
8, after which symptoms returned to the level 
observed with placebo. In contrast, a partial re-
lapse of symptoms was noted with the 72-mg 
dose of ligelizumab toward the end of the 
4-week administration interval. These data sug-
gest that although the 72-mg dose of ligelizumab 
led to rapid control of symptoms, a dose higher 
than 72 mg could potentially provide enough 
drug effect throughout the administration inter-
val to minimize relapse of symptoms and offer 
sustained control of symptoms throughout the 
4-week administration interval. In support of 
this sustained treatment effect, the median time 
to loss of complete response in patients who had 
a weekly urticaria activity score of 0 at week 20 
(end of the treatment phase) was greatest in the 
group that was treated with 240 mg of ligeliz-
umab (10.5 weeks) and was similar in the 
groups that received 72 mg of ligelizumab or 
300 mg of omalizumab (4 weeks). Previous stud-
ies of omalizumab have indicated that some pa-
tients have a return of symptoms within 4 weeks 
(i.e., before the administration of the next 
dose).32,33 Future studies will be needed to deter-
mine the dose of ligelizumab that results in a 
sustained clinical response throughout the ad-
ministration interval.
The percentage of patients who had at least 
one adverse event was similar among the ligeliz-
umab dose groups, the omalizumab group, and 
the placebo group. Adverse events were reported 
in 84%, 75%, and 74% of the patients who were 
treated with 24 mg, 72 mg, and 240 mg, respec-
tively, of ligelizumab every 4 weeks and in 88% 
of the patients who received the single 120-mg 
dose of ligelizumab, 73% of those in the omaliz-
umab group, and 79% of those in the placebo 
group. The higher incidence of injection-site re-
actions and injection-site erythema observed with 
ligelizumab at the doses of 72 mg and 240 mg 
than in the other groups may have been associ-
ated with differences in the administration vol-
umes and compositions. The administration of 
the 240-mg dose of ligelizumab involved two 
injections of active drug (1.0 ml each), as com-
pared with injections of one active drug (0.6 ml) 
and one placebo (0.6 ml) that were used for the 
72-mg dose. No cases of anaphylaxis were re-
ported in this trial.
In conclusion, in patients with moderate-to-
severe chronic spontaneous urticaria, ligelizumab 
showed a clear dose–response relationship with 
regard to complete hives response (weekly hives-
severity score of 0) at week 12. Ligelizumab re-
sulted in rapid and sustained symptom control 
in patients with chronic spontaneous urticaria. 
In this small trial, side effects or laboratory ab-
normalities were not dose-limiting. Larger and 
longer trials are needed to establish the clinical 
efficacy of ligelizumab in patients with chronic 
spontaneous urticaria and its comparative pro-
file with that of omalizumab.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
Supported by Novartis Pharma.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Martin Wallace, Ph.D., of Novartis Ireland, for pro-
viding medical writing assistance in accordance with Good Pub-
lication Practice guidelines (www . ismpp . org/ gpp3).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LEEDS on October 28, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;14 nejm.org October 3, 2019 1331
Ligelizumab for Chronic Spontaneous Urticaria
Appendix
The authors’ full names and academic degrees are as follows: Marcus Maurer, M.D., Ana M. Giménez-Arnau, M.D., Ph.D., Gordon 
Sussman, M.D., Martin Metz, M.D., Diane R. Baker, M.D., Andrea Bauer, M.D., Jonathan A. Bernstein, M.D., Randolf Brehler, M.D., 
Chia-Yu Chu, M.D., Ph.D., Wen-Hung Chung, M.D., Inna Danilycheva, M.D., Clive Grattan, M.D., Jacques Hébert, M.D., Constance 
Katelaris, M.D., Ph.D., Michael Makris, M.D., Raisa Meshkova, M.D., D.Sc., Sinisa Savic, M.D., Ph.D., Rodney Sinclair, M.D., Karl Sitz, 
M.D., Petra Staubach, M.D., Bettina Wedi, M.D., Jürgen Löffler, Ph.D., Avantika Barve, Ph.D., Kenneth Kobayashi, M.D., Eva Hua, 
M.Sc., Thomas Severin, M.D., and Reinhold Janocha, Ph.D.
The authors’ affiliations are as follows: the Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin (M. 
Maurer, M. Metz), the Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical Univer-
sity Dresden, Dresden (A. Bauer), the Department of Dermatology, University Hospital Münster, Münster (R.B.), the Department of 
Dermatology, University Medical Center Mainz, Mainz (P.S.), and the Department of Dermatology and Allergy, Comprehensive Allergy 
Center, Hannover Medical School, Hannover (B.W.) — all in Germany; the Dermatology Department, Hospital del Mar–Institut Hospi-
tal del Mar d’Investigacions Mèdiques, Universitat Autònoma Barcelona, Barcelona (A.M.G.-A.); the Division of Allergy and Clinical 
Immunology, St. Michael’s Hospital and University of Toronto, Toronto (G.S.), Service d’Allergie, Centre Hospitalier Université Laval–
Centre Hospitalier Universitaire de Québec, Quebec, QC (J.H.), and the Department of Medicine, University of Ottawa, Ottawa (K.K.) 
— all in Canada; Baker Allergy Asthma and Dermatology Clinic, Portland, OR (D.R.B.); University of Cincinnati College of Medicine, 
Department of Internal Medicine, Division of Immunology, Rheumatology, and Allergy and Bernstein Clinical Research Center, Cincin-
nati (J.A.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine 
(C.-Y.C.), and the Department of Dermatology, Chang Gung Memorial Hospital (W.-H.C.), Taipei, Taiwan; the National Research 
Center–Institute of Immunology Federal Medical–Biological Agency of Russia, Moscow (I.D.), and the Department of Clinical Immunol-
ogy and Allergology, Smolensk State Medical University, Smolensk (R.M.) — both in Russia; St. John’s Institute of Dermatology, Guy’s 
and St. Thomas’ Hospitals NHS Foundation Trust, London (C.G.), and the National Institute for Health Research–Leeds Biomedical 
Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, and the Department of Clinical Immunology and 
Allergy, St. James’s University Hospital, Leeds (S.S.) — all in the United Kingdom; the School of Medicine, Western Sydney University, 
and the Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, NSW (C.K.), and Sinclair Dermatology and the Epworth 
Hospital, Melbourne, VIC (R.S.) — all in Australia; the Second Department of Dermatology and Venereology, Attikon University Hos-
pital, Athens (M. Makris); Little Rock Allergy and Asthma Clinic, Little Rock, AR (K.S.); Novartis Pharma, Basel, Switzerland (J.L., T.S., 
R.J.); Novartis Pharmaceuticals, East Hanover, NJ (A. Barve, K.K.); and Shanghai Novartis Trading, Shanghai, China (E.H.).
References
1. Zuberbier T, Aberer W, Asero R, et al. 
The EAACI/GA²LEN/EDF/WAO guideline 
for the definition, classification, diagno-
sis and management of urticaria. Allergy 
2018; 73: 1393-414.
2. Grattan C. The urticarias: pathophysi-
ology and management. Clin Med (Lond) 
2012; 12: 164-7.
3. Gaig P, Olona M, Muñoz Lejarazu D, 
et al. Epidemiology of urticaria in Spain. 
J Investig Allergol Clin Immunol 2004; 14: 
214-20.
4. Raciborski F, Kłak A, Czarnecka- 
Operacz M, et al. Epidemiology of urticaria 
in Poland — nationally representative sur-
vey results. Postepy Dermatol Alergol 
2018; 35: 67-73.
5. Zuberbier T, Balke M, Worm M, Eden-
harter G, Maurer M. Epidemiology of 
 urticaria: a representative cross-sectional 
population survey. Clin Exp Dermatol 
2010; 35: 869-73.
6. Maurer M, Weller K, Bindslev-Jensen 
C, et al. Unmet clinical needs in chronic 
spontaneous urticaria: a GA2LEN task force 
report. Allergy 2011; 66: 317-30.
7. van der Valk PG, Moret G, Kiemeney 
LA. The natural history of chronic urti-
caria and angioedema in patients visiting 
a tertiary referral centre. Br J Dermatol 
2002; 146: 110-3.
8. Maurer M, Abuzakouk M, Bérard F, 
et al. The burden of chronic spontaneous 
urticaria is substantial: real-world evi-
dence from ASSURE-CSU. Allergy 2017; 
72: 2005-16.
9. Kaplan AP. Chronic urticaria — new 
concepts regarding pathogenesis and treat-
ment. Curr Allergy Asthma Rep 2002; 2: 
263-4.
10. Sabroe RA, Greaves MW. Chronic idio-
pathic urticaria with functional autoanti-
bodies: 12 years on. Br J Dermatol 2006; 
154: 813-9.
11. Kolkhir P. Autoimmune chronic spon-
taneous urticaria: what we know and 
what we do not know. J Allergy Clin Im-
munol 2017; 139: 1772-81.
12. Schmetzer O, Lakin E, Topal FA, et al. 
IL-24 is a common and specific autoanti-
gen of IgE in patients with chronic spon-
taneous urticaria. J Allergy Clin Immunol 
2018; 142: 876-82.
13. Altrichter S, Peter HJ, Pisarevskaja D, 
Metz M, Martus P, Maurer M. IgE medi-
ated autoallergy against thyroid peroxi-
dase — a novel pathomechanism of 
chronic spontaneous urticaria? PLoS One 
2011; 6(4): e14794.
14. Kaplan AP. Chronic spontaneous urti-
caria: pathogenesis and treatment consid-
erations. Allergy Asthma Immunol Res 
2017; 9: 477-82.
15. Guillén-Aguinaga S, Jáuregui Presa I, 
Aguinaga-Ontoso E, Guillén-Grima F, 
Ferrer M. Updosing nonsedating antihis-
tamines in patients with chronic sponta-
neous urticaria: a systematic review and 
meta-analysis. Br J Dermatol 2016; 175: 
1153-65.
16. Curto-Barredo L, Spertino J, Figueras-
Nart I, et al. Omalizumab updosing allows 
disease activity control in patients with 
refractory chronic spontaneous urticaria. 
Br J Dermatol 2018; 179: 210-2.
17. Zhao ZT, Ji CM, Meng L, et al. 
Omaliz umab for the treatment of chron-
ic spontaneous urticaria: a meta-analy-
sis of randomized clinical trials. J Aller-
gy Clin Immunol 2016; 137: 1742-50.
18. Maurer M, Kaplan A, Rosén K, et al. 
The XTEND-CIU study: long-term use of 
omalizumab in chronic idiopathic urticar-
ia. J Allergy Clin Immunol 2018; 141: 1138-9.
19. Kaplan A, Ledford D, Ashby M, et al. 
Omalizumab in patients with symptom-
atic chronic idiopathic/spontaneous urti-
caria despite standard combination ther-
apy. J Allergy Clin Immunol 2013; 132: 
101-9.
20. Maurer M, Rosén K, Hsieh H-J, et al. 
Omalizumab for the treatment of chronic 
idiopathic or spontaneous urticaria. N Engl 
J Med 2013; 368: 924-35.
21. Saini SS, Bindslev-Jensen C, Maurer 
M, et al. Efficacy and safety of omalizu-
mab in patients with chronic idiopathic/
spontaneous urticaria who remain symp-
tomatic on H1 antihistamines: a random-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LEEDS on October 28, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;14 nejm.org October 3, 20191332
Ligelizumab for Chronic Spontaneous Urticaria
ized, placebo-controlled study. J Invest 
Dermatol 2015; 135: 67-75.
22. Casale TB, Bernstein JA, Maurer M, 
et al. Similar efficacy with omalizumab in 
chronic idiopathic/spontaneous urticaria 
despite different background therapy. 
J Allergy Clin Immunol Pract 2015; 3: 743-
50.
23. Arm JP, Bottoli I, Skerjanec A, et al. 
Pharmacokinetics, pharmacodynamics and 
safety of QGE031 (ligelizumab), a novel 
high-affinity anti-IgE antibody, in atopic 
subjects. Clin Exp Allergy 2014; 44: 1371-85.
24. Hollis K, Proctor C, McBride D, et al. 
Comparison of Urticaria Activity Score 
over 7 days (UAS7) values obtained from 
once-daily and twice-daily versions: re-
sults from the ASSURE-CSU Study. Am J 
Clin Dermatol 2018; 19: 267-74.
25. Hawro T, Ohanyan T, Schoepke N, et al. 
Comparison and interpretability of the 
available Urticaria Activity Scores. Allergy 
2018; 73: 251-5.
26. Stull D, McBride D, Tian H, et al. 
Analysis of disease activity categories in 
chronic spontaneous/idiopathic urticaria. 
Br J Dermatol 2017; 177: 1093-101.
27. Mathias SD, Crosby RD, Rosén KE, 
Zazzali JL. The minimal important differ-
ence for measures of urticaria disease ac-
tivity: updated findings. Allergy Asthma 
Proc 2015; 36: 394-8.
28. Biagtan MJ, Viswanathan RK, Evans 
MD, Mathur SK. Clinical utility of the 
Chronic Urticaria Index. J Allergy Clin 
Immunol 2011; 127: 1626-7.
29. Viswanathan RK, Biagtan MJ, Mathur 
SK. The role of autoimmune testing in 
chronic idiopathic urticaria. Ann Allergy 
Asthma Immunol 2012; 108: 337-41.
30. Bretz F, Pinheiro JC, Branson M. Com-
bining multiple comparisons and model-
ing techniques in dose-response studies. 
Biometrics 2005; 61: 738-48.
31. Pinheiro J, Bornkamp B, Glimm E, 
Bretz F. Model-based dose finding under 
model uncertainty using general para-
metric models. Stat Med 2014; 33: 1646-61.
32. Türk M, Kocatürk E, Cüre K, Yılmaz İ. 
Two-week intervals during omalizumab 
treatment may provide better symptom 
control in selected patients with chronic 
urticaria. J Allergy Clin Immunol Pract 
2018; 6: 1389-90.
33. Larenas-Linnemann DES, Parisi CAS, 
Ritchie C, et al. Update on omalizumab 
for urticaria: what’s new in the literature 
from mechanisms to clinic. Curr Allergy 
Asthma Rep 2018; 18(5): 33.
Copyright © 2019 Massachusetts Medical Society.
ARTICLE METRICS NOW AVAILABLE
Visit the article page at NEJM.org and click on Metrics to view comprehensive and 
cumulative article metrics compiled from multiple sources, including Altmetrics. 
NEJM.org/about-nejm/article-metrics.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LEEDS on October 28, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
